Hoffmann-La Roche: Small Cell Lung Carcinoma trials

The registry lists 16 Small Cell Lung Carcinoma studies with Hoffmann-La Roche as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 3Phase 3 5Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERRecruitingNCT07107490Phase 1
• A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerActive, not recruitingNCT05091567Phase 3Results posted
• Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04665856Phase 3Results posted
• A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).TerminatedNCT04422210Phase 1Results posted
• A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04256421Phase 3Results posted
• A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsCompletedNCT03708328Phase 1Results posted
• A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT02763579Phase 3Results posted
• A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)CompletedNCT00403403Phase 2Results posted
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine CarcinomasCompletedNCT05619744Phase 1
• Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2
• A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Phase 2
• Prospective Clinicogenomic ProgramCompletedNCT04180176Phase 4
• A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3
• A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompletedNCT03782207
• A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593
• A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)CompletedNCT02913443Phase 1